<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33437">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01876719</url>
  </required_header>
  <id_info>
    <org_study_id>AR08.001</org_study_id>
    <nct_id>NCT01876719</nct_id>
  </id_info>
  <brief_title>AR08 for Treatment of ADHD in Children</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Proof-of-Concept Study of AR08 in the Treatment of Attention Deficit Hyperactivity Disorder in Children (Ages 6 - 17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced
      titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio.
      One-hundred twenty (120) patients are planned to be randomized. Each patient will receive
      AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ADHD-RS-IV</measure>
    <time_frame>Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the ADHD-RS-IV; change from Baseline to Visit 7 (Day 35).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-ADHD-S/I</measure>
    <time_frame>Day 35</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGI-ADHD-S (severity) and I (improvement) - change from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners' Parent Rating Scale</measure>
    <time_frame>Day 49</time_frame>
    <safety_issue>No</safety_issue>
    <description>Conners' Parent Rating Scale (CPRS-R-S) will be assessed through Day 49.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Day 49</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Columbia Suicide Severity Rating Scale (C-SSRS) - incident rate will be assessed through Day 49.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>0.5 mg AR08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg AR08, QD for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg AR08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg AR08, QD for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg AR08</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg AR08, QD for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, QD for 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR08</intervention_name>
    <arm_group_label>0.5 mg AR08</arm_group_label>
    <arm_group_label>1.0 mg AR08</arm_group_label>
    <arm_group_label>2.0 mg AR08</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets DSM-IV-TR criteria for a primary diagnosis of ADHD based on structured clinical
             interview, MINI-KID, as assessed by the Investigator

          2. Minimum score of 28 on the ADHD-RS-IV at Baseline

          3. Male or female ages 6 - 17 years, inclusive, at the time of Screening

          4. Weighs â‰¥21 kg (46 pounds).

          5. Is functioning at age appropriate levels intellectually, as deemed by the
             Investigator.

        Exclusion Criteria:

          1. Has a comorbid psychiatric diagnosis (comorbid psychiatric diagnosis will be
             established by the MINI-KID interview).

          2. Has a positive response to either question 4 or 5 of the Baseline /Screening version
             of the pediatric Columbia Suicide Severity Rating Scale (C-SSRS)

          3. History of daily usage (at least 28 days/month) of either anti-hypertensive or
             prophylactic anti-migraine medications prior to Screening

          4. Current usage of medications known to cause QTc prolongation or ADHD medications.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Downey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arbor Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terrilyn Sharpe</last_name>
    <phone>404 496-5928</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Brandenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail McDonnell</last_name>
      <phone>941-747-7900</phone>
    </contact>
    <investigator>
      <last_name>Andrew Cutler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Joyce, MD</last_name>
      <phone>904-281-5757</phone>
    </contact>
    <investigator>
      <last_name>John Joyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Lopetegui</last_name>
      <phone>305-722-8444</phone>
      <phone_ext>2259</phone_ext>
    </contact>
    <investigator>
      <last_name>Scott Segal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy West</last_name>
      <phone>407-425-5100</phone>
    </contact>
    <investigator>
      <last_name>Linda Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sulen Ramos</last_name>
      <phone>305-598-3125</phone>
      <phone_ext>3327</phone_ext>
    </contact>
    <investigator>
      <last_name>Americo Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Janus Center for Psychiatric Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Groth</last_name>
      <phone>561-238-3035</phone>
    </contact>
    <investigator>
      <last_name>Janice Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaqueline Dalton</last_name>
      <phone>404-881-5800</phone>
    </contact>
    <investigator>
      <last_name>Robert Riesenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Research Group at St. Charles Psychiatric Associates</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Orf</last_name>
      <phone>636-946-8032</phone>
    </contact>
    <investigator>
      <last_name>Gregory Mattingly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Murray</last_name>
      <phone>702-838-0742</phone>
    </contact>
    <investigator>
      <last_name>Ann Childress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Bain</last_name>
      <phone>901-843-1045</phone>
    </contact>
    <investigator>
      <last_name>Valerie Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayou City Research Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Harpst</last_name>
      <phone>832-251-7000</phone>
    </contact>
    <investigator>
      <last_name>Matthew Brams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnny Timmons</last_name>
      <phone>713-665-8787</phone>
    </contact>
    <investigator>
      <last_name>Alain Katic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Associates</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Andrews</last_name>
      <phone>703-787-9090</phone>
    </contact>
    <investigator>
      <last_name>Keith Saylor, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>June 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>AR08</keyword>
  <keyword>adrenergic receptor agonists</keyword>
  <keyword>randomized, placebo-controlled clinical trial</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
